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Aldosterone Blockade in Metabolic Syndrome
Hitting the Target or Still Missing Some Links?*
Dominic Y. Leung, MBBS, PHD
Liverpool, New South Wales, Australiat
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aAldosterone blockade improves symptoms and out-
comes in systolic heart failure and after acute myocar-
dial infarction when added to angiotensin-converting
enzyme inhibitors (ACEI) or angiotensin-receptor
blockers (ARB). However, studies on the impact of
aldosterone blockade on left ventricular (LV) volumes
and ejection fraction have been inconsistent (1,2)
with a meta-analysis of 19 randomized trials show-
ing only a modest increase in LV ejection fraction
of 3% despite an impressive 20% reduction in
all-cause mortality (3). The beneficial effects of
aldosterone blockade may be mediated by processes
other than just reverse modeling and improvement
in ejection fraction.
See page 1239
Cardiac extracellular matrix (ECM) plays an active
role in modulating cardiac function and undergoes
extensive and continuous turnover as important steps
in an injury-reparative process. Fibroblasts are the
predominant cell types in the ECM and proliferation
of cardiac fibroblasts in response to a wide range of
injury leads to increased collagen synthesis resulting in
cardiac fibrosis and dysfunction. By stimulating colla-
gen synthesis, aldosterone promotes cardiac fibrosis,
and attenuation of the excessive ECM turnover by
aldosterone blockade has been suggested to be the
mechanism underlying its beneficial effects in systolic
heart failure (4,5). Furthermore, circulating biomark-
ers of collagen turnover provide a window to ECM
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Guest Editor for this paper.urnover. Because types I and III collagen are most
bundant in the heart, the most studied biomarkers
re the procollagen type III N-terminal propeptide
PIIINP) and procollagen type I C-terminal propep-
ide (PICP). Levels of these biomarkers have been
hown to be of prognostic values in systolic heart
ailure (4,5) and aldosterone blockade led to a decrease
n these biomarker levels. Moreover, the clinical ben-
fits appeared to be most evident in patients with
levated biomarker levels (5).
The promise of aldosterone blockade in systolic
eart failure has led to studies examining its use in
ther cardiac diseases characterized by increased
ardiac fibrosis but without overt systolic dysfunc-
ion, including heart failure with preserved ejection
raction, hypertensive and diabetic heart disease,
nd chronic kidney disease (6–8). Metabolic syn-
rome is another such condition. Metabolic syn-
rome is a constellation of vascular risk factors of
etabolic origin, and aldosterone is considered to
e central in the pathophysiology (9).
In this issue of iJACC, Kosmala et al. (10)
xamined the effects of spironolactone on LV struc-
ure, function, and serum levels of biomarkers of
ollagen synthesis (PICP, PIIINP, and transform-
ng growth factor beta1) in patients with metabolic
yndrome already on ACEI or ARB. Eighty pa-
ients were randomized to either spironolactone 25
g/day or placebo. After 6 months, the spironolactone
roup had a significant decrease in PICP, PIIINP,
nd transforming growth factor beta1 levels, left
trial dimension, and LV wall thickness and mass.
he treatment group had an improvement in LV
echanics evidenced by an increase in longitudinal
train and strain rate, Em and a decrease in E/e=. A
ecrease in calibrated integrated backscatter in the
asal posterior walls as a surrogate of fibrosis was
lso seen. More interestingly and perhaps more
rovocatively, there were differential responses ac-
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1251cording to the baseline PICP levels and LV func-
tion. Significant improvement was seen with spi-
ronolactone in the middle and upper tertiles of
baseline PICP levels and in the lowest and middle
tertiles of measures of LV function.
The study is important and timely. It further
adds to the growing evidence for aldosterone block-
ade in “hyperfibrotic conditions” beyond systolic
heart failure and post–acute myocardial infarction.
Previous studies have demonstrated similar benefi-
cial effects, albeit echocardiographic and biochem-
ical ones, of aldosterone blockade in hypertension
and diabetes, heart failure with preserved systolic
function, and chronic kidney disease (6–8). This is
the first study not only to extend the observation to
metabolic syndrome, but also to provide possible
mechanistic links between myocardial derange-
ments, aldosterone blockade, and improvement in
LV systolic and diastolic function. Myocardial de-
rangements were evidenced by a higher LV end-
diastolic dimension, LV mass index, left atrial
dimension, E/e=, calibrated integrated backscatter
and a lower Em, and longitudinal strain and strain
rate, associated with higher levels of PICP and
PIIINP. Spironolactone treatment improved myo-
cardial derangements and reduced biomarker levels.
Subgroup analyses and multivariate models revealed
that patients with higher collagen turnover and
those with lower strain, strain rate, and Em veloc-
ities benefited more from spironolactone. More
importantly, the decrease in biomarker levels with
spironolactone was more marked in patients with
the most deranged myocardial mechanics. It may be
inferred that: 1) patients with more cardiac fibrosis
had the most deranged myocardial mechanics;
2) these patients benefited most from aldosterone
blockade; and 3) reduction in cardiac fibrosis was
the underlying mechanism of improvement with
treatment. Another important observation is that
these beneficial effects of spironolactone were seen
in patients already treated with either ACEI or
ARB. Both angiotensin II and aldosterone stimu-
late cardiac fibrosis and additional blockade of the
renin-angiotensin-aldosterone system with spi-
ronolactone to cover “aldosterone escape” allows
further suppression of cardiac fibrosis.
Are circulating levels of collagen turnover indic-
ative of the degree of cardiac fibrosis? Perhaps more
importantly, is any decrease in biomarker levels
with aldosterone blockade associated with a parallel
decrease in cardiac fibrosis? Collagen is the most
abundant protein in the body with a highly dynamic
turnover. Biomarkers of collagen turnover are notcardiac-specific and high levels may not necessarily
reflect changes at the microscopic level in the
myocardium. Evidence for such pathophysiological
link is far from conclusive. A multitude of biomark-
ers are available: biomarkers related to collagen
synthesis (PICP and PIIINP) and biomarkers re-
lated to collagen degradation (matrix metalloprotei-
nases and tissue inhibitors of metalloproteinases).
There is no common consensus on which ones are
the most preferable. Furthermore, factors relating
to the demographics of the subjects, the methods of
immunoassay, presence of comorbidities, and the
elimination of the circulating biomarkers may all
potentially confound the measurement and inter-
pretation of biomarker levels (11). Therefore, dem-
onstrating a direct connection between circulating
levels of biomarkers, the status of the myocardial
collagen network, and the alteration in myocardium
structure and function is still an all-important
missing link.
The number of patients in the study was small,
and the study was powered according to a difference
in peak strain between the 2 groups. Further sub-
group analyses on differential benefits according to
baseline strain values or biomarker levels were post
hoc, involved even smaller number of patients, and
tests for interaction were not reported. Neverthe-
less, the findings on subgroup analysis should be
considered hypothesis-generating, and they are def-
initely worth further investigations.
A most important missing link is if echocardio-
graphic and biochemical beneficial effects seen with
spironolactone in metabolic syndrome would equate
to an improvement in symptoms and patient out-
come. Large randomized trials of ACEI and ARB
in heart failure and preserved ejection fraction failed
to show any significant clinical benefits. Would the
fall in biomarkers of collagen turnover; increase in
strain, strain rate, and Em; or other changes in
echocardiographic parameters seen in this study
lead to improvement in symptoms and patient
outcomes in metabolic syndrome? Whereas tissue
velocities, myocardial deformation, and tissue char-
acterization measure true intrinsic myocardial prop-
erties, it remains to be shown that the improvement
of the degree seen in this study will lead to
improvement in symptoms and clinical outcome.
The lack of information on functional status and
outcome data in the current study precludes draw-
ing any such conclusions. The link between reduc-
tion in biomarker levels with improved ventricular
mechanics and improvement in symptoms and
prognosis in metabolic syndrome is still elusive.
L
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1252A more philosophical question is about the effect
of life-style changes, in contrast/in addition to
aldosterone blockade, on myocardial mechanics and
biomarker levels. Through no faults of the investi-
gators, there were no meaningful changes in the
biochemical and morphometric profiles of the pa-
tients after 6 months of monitoring and treatment.
Perhaps it is more important to focus on the root of
the problems in metabolic syndrome in addition to
just targeting the biochemical mediators.
This study by Kosmala et al. (10) is unique in
that it provides evidence for beneficial effects of
aldosterone blockade in metabolic syndrome,
which, in addition to hypertensive heart disease,
chronic kidney diseases, heart failure with preserved
systolic function, is certainly another target for
more comprehensive blockade of the renin-Randomized Aldactone Evaluation on myocardial dysfing prevalence of metabolic syndrome, the inability
to adopt sufficient life-style modifications and the
significant morbidities and mortality associated
with the condition, the medical community is in
need of potentially “disease modifying” therapies
such as aldosterone blockade. The missing links
notwithstanding, we welcome studies by Kosmala
et al. (10) and await the results of large-scale clinical
trials such as TOPCAT (Treatment of Preserved
Cardiac function heart failure with an Aldosterone
anTagonist) of aldosterone blockade in “hyperfi-
brotic” conditions with interests.
Reprint requests and correspondence: Prof. Dominic Y.
eung, Department of Cardiology, Liverpool Hospital,
ocked Bag, 7103, Liverpool BC, NSW 1871, Australia.angiotensin-aldosterone system. Given the increas- E-mail: d.leung@unsw.edu.au.1
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